Monte Rosa Therapeutics Reports Positive Phase 1 MRT-8102 Data

Monte Rosa Therapeutics announced positive GFORCE-1 Phase 1 results for MRT-8102, demonstrating approximately 80-90% NEK7 degradation and broad normalization of ASCVD pathogenic drivers, accompanied by a favorable safety profile.